Value through Innovation29 August 2015

Boehringer Ingelheim Group of companies

2014 was an intense year with many business challenges for Boehringer Ingelheim. The guiding principle was at all times to create sufficient space in future to be able to continue to invest in organic, sustainable growth.

    Financial Highlights

    Boehringer Ingelheim group of companies
     
    2014 2013 Change
    Net sales
    13,317 14,065 - 5 %
    Net sales by region
       
    Europe
    31% 30 %
    Americas
    44% 46 %  
    Asia, Australasia, Africa
    25% 24 %  
    by business
         
    Prescription Medicines 76% 77 %  
    Consumer Health Care 11% 11 %  
    Animal Health 8% 8 %  
    Biopharmaceuticals 4% 3 %  
    Industrial Customers and other sales 1% 1 %  
           
    Research and Development
    2,654 2,743  - 3 %
    Personnel costs
    4,116 4,071 + 1 %
    Average number of employees
    47,743 47,492 + 1 %
    Operating income
    2,140 2,114 + 1 %
    Operating income as % of net sales
    16.1% 15.0 %  
    Income after taxes
    1,047 1,324 - 21 %
    Income after taxes as % of net sales
    7.9% 9.4 %  
    Shareholders' equity
    8,111 7,122 + 14 %
    Return on shareholders' equity
    14.7% 21.4 %  
    Cash Flow
    1,850 2,129 - 13 %
    Investments in tangible assets
    548 558 - 2 %
    Depreciation of tangible assets
    449 640 - 30 %


    Amounts in millions of EUR, unless otherwise indicated